Detalles de la búsqueda
1.
Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTAN.
Br J Cancer;
130(1): 73-81, 2024 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37951974
2.
Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMIS.
Oncologist;
2024 Feb 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-38394384
3.
Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel (PRESIDE): an international, randomised, phase 3b study.
Lancet Oncol;
23(11): 1398-1408, 2022 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-36265504
4.
Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer.
N Engl J Med;
381(26): 2506-2518, 2019 12 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-31566937
5.
Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study.
Lancet Oncol;
21(11): 1513-1525, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-32926841
6.
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.
N Engl J Med;
377(4): 352-360, 2017 07 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-28578607
7.
Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial.
Lancet Oncol;
20(5): 686-700, 2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30987939
8.
Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial.
Lancet Oncol;
18(4): 473-485, 2017 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-28283282
9.
Ten Years of Complete Remission of Pulmonary Metastasis after Post-Cystectomy Palliative Cisplatin-Gemcitabine Chemotherapy with Gefitinib for Muscle Invasive Bladder Cancer: A Case Report.
Urol Int;
97(4): 485-488, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-26863306
10.
Prospective randomized double-blind multicentre phase II study comparing gemcitabine and cisplatin plus sorafenib chemotherapy with gemcitabine and cisplatin plus placebo in locally advanced and/or metastasized urothelial cancer: SUSE (AUO-AB 31/05).
BJU Int;
113(3): 429-36, 2014 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-24053564
11.
Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cancer.
Clin Cancer Res;
29(10): 1887-1893, 2023 05 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-36917691
12.
Biweekly vs Triweekly Cabazitaxel in Older Patients With Metastatic Castration-Resistant Prostate Cancer: The CABASTY Phase 3 Randomized Clinical Trial.
JAMA Oncol;
9(12): 1629-1638, 2023 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37883073
13.
Promiscuous survivin peptide induces robust CD4+ T-cell responses in the majority of vaccinated cancer patients.
Int J Cancer;
131(1): 140-9, 2012 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-21858810
14.
Impact of abiraterone acetate plus prednisone in patients with castration-sensitive prostate cancer and visceral metastases over four years of follow-up: A post-hoc exploratory analysis of the LATITUDE study.
Eur J Cancer;
162: 56-64, 2022 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-34953443
15.
LHRH sparing therapy in patients with chemotherapy-naïve, mCRPC treated with abiraterone acetate plus prednisone: results of the randomized phase II SPARE trial.
Prostate Cancer Prostatic Dis;
25(4): 778-784, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35430584
16.
Efficacy and Safety of Autologous Dendritic Cell-Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer: The VIABLE Phase 3 Randomized Clinical Trial.
JAMA Oncol;
8(4): 546-552, 2022 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35142815
17.
Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: Further analyses from the PROfound study.
Eur J Cancer;
170: 73-84, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35598359
18.
Real-World Safety and Efficacy Outcomes with Abiraterone Acetate Plus Prednisone or Prednisolone as the First- or Second-Line Treatment for Metastatic Castration-Resistant Prostate Cancer: Data from the Prostate Cancer Registry.
Target Oncol;
16(3): 357-367, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33826036
19.
Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study.
Eur Urol;
80(4): 497-506, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34274136
20.
The prostate cancer gene 3 (PCA3) urine test in men with previous negative biopsies: does free-to-total prostate-specific antigen ratio influence the performance of the PCA3 score in predicting positive biopsies?
BJU Int;
106(8): 1143-7, 2010 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-20230386